Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA) and maintenance therapy to prevent exacerbations by targeting underlying pathophysiology (e.g., a LABA/ICS, such as GSK’s Advair or AstraZeneca’s Symbicort); most pediatric asthma patients receive more than one agent to treat their condition. Despite the availability of multiple, well-established therapies, the pediatric asthma treatment landscape has seen the approval and launch of additional agents in recent years, including salmeterol / fluticasone generics and novel biological drugs (e.g., Regeneron / Sanofi’s Dupixent, GSK’s Nucala). These events have added more treatment options and fueled competition in this market.
Real world data
Key drugs covered:
Key analysis provided
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.